Molecular Insight Pharmaceuticals of Cambridge, MA, has appointed James Wachholz as vice president, regulatory affairs and quality assurance, and Joshua Hamermesh as vice president, commercial and business development.
Wachholz most recently served as chief regulatory officer of Accentia Biopharmaceuticals. Hamermesh comes to the radioisotope imaging developer from Genzyme Corporation.
By AuntMinnie.com staff writers
June 1, 2005
Related Reading
Molecular Insight raises $28 million, June 1, 2005
Molecular Insight, University of Maryland get NIH grant, August 27, 2004
Copyright © 2005 AuntMinnie.com
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&fit=crop&h=100&q=70&w=100)
![A 53-year-old patient (patient number four) with a recurrent pituitary adenoma with extension of a cystic component of disease to the medial temporal lobe apparent on MRI (contoured in blue), and extension of disease to the left sphenoid bone and orbital apex apparent on [68Ga]Ga-DOTA-TATE (contoured in yellow).](https://img.auntminnie.com/mindful/smg/workspaces/default/uploads/2026/04/pituitary-tumor.QGsEnyB4bU.jpg?auto=format%2Ccompress&dpr=2&fit=crop&h=167&q=70&w=250)
